Neoplasms escape selective COX-2 inhibition in an animal model of breast cancer.
AffiliationDepartment of Surgery, Royal College of Surgeons in Ireland, Beaumont Hospital, Dublin 9, Ireland. email@example.com
Cyclooxygenase 2 Inhibitors
Mice, Inbred BALB C
MetadataShow full item record
CitationNeoplasms escape selective COX-2 inhibition in an animal model of breast cancer. 2009, 178 (2):201-8 Ir J Med Sci
JournalIrish journal of medical science
AbstractCyclo-oxygenase-2 (COX-2) is up-regulated in malignant tumours rendering it an attractive target for cancer therapeutics. However, whether long-term antagonism maintains its initial efficacy on established tumours is unclear.
4T1 cells were injected into the mammary fat pad of BALB/c mice (n = 8). Once tumour deposits were established, animals were randomized into two equal groups to receive either a selective COX-2 inhibitor (SC-236) or a drug vehicle. Further animals similarly treated (n = 7) were studied in diuresis cages allowing urine capture and analysis by mass spectrometry to determine Prostaglandin F-1 levels (PGF-1). In addition, both wild-type receiving SC-236 and COX-2 knockout mice receiving either SC 236 or vehicle were subjected to the same studies to determine whether tumour-derived or host-derived (stromal) COX-2 was the critical element. Finally, BALB/c mice with 4T1 tumours (n = 7) were treated with a combination of COX-2 and lipoxygenase (LOX) inhibition to attenuate this escape phenomenon.
While selective COX-2 inhibition initially retarded tumour growth, a rapid increase in tumour growth rate occurred later (day 9). This escape phenomenon correlated with an increase in urinary PGF-1 levels. An identical trend was also observed whether COX-2 knockout mice received SC-236 or not, suggesting that this effect is due to increased tumour-derived COX-2 production rather than recovery of host COX-2 functional capacity. Finally, dual inhibition of COX and LOX pathways attenuated this escape process.
The anti-neoplastic effects of selective COX-2 inhibition may not be sustained as tumours demonstrate an escape capacity. However, this phenomenon maybe attenuated by a combination of COX/LOX inhibitors.
- Cyclo-oxygenase inhibition reduces tumour growth and metastasis in an orthotopic model of breast cancer.
- Authors: Connolly EM, Harmey JH, O'Grady T, Foley D, Roche-Nagle G, Kay E, Bouchier-Hayes DJ
- Issue date: 2002 Jul 15
- Antimetastatic activity of a cyclooxygenase-2 inhibitor.
- Authors: Roche-Nagle G, Connolly EM, Eng M, Bouchier-Hayes DJ, Harmey JH
- Issue date: 2004 Jul 19
- Cyclooxygenase-2 inhibition: effects on tumour growth, cell cycling and lymphangiogenesis in a xenograft model of breast cancer.
- Authors: Barnes NL, Warnberg F, Farnie G, White D, Jiang W, Anderson E, Bundred NJ
- Issue date: 2007 Feb 26
- Comparative protection against liver inflammation and fibrosis by a selective cyclooxygenase-2 inhibitor and a nonredox-type 5-lipoxygenase inhibitor.
- Authors: Horrillo R, Planagumà A, González-Périz A, Ferré N, Titos E, Miquel R, López-Parra M, Masferrer JL, Arroyo V, Clària J
- Issue date: 2007 Dec
- Honokiol inhibits gastric tumourigenesis by activation of 15-lipoxygenase-1 and consequent inhibition of peroxisome proliferator-activated receptor-gamma and COX-2-dependent signals.
- Authors: Liu SH, Shen CC, Yi YC, Tsai JJ, Wang CC, Chueh JT, Lin KL, Lee TC, Pan HC, Sheu ML
- Issue date: 2010 Aug